Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Biomodels, LLC
WATERTOWN, Mass. and SALT LAKE CITY, Jan. 7, 2014 /PRNewswire/ -- Biomodels, a front-runner and innovator in translational pre-clinical efficacy models and genomics, today announced the signing of a joint services agreement with Numira Inc, the market leader in high-resolution, 3D imaging services and visualization software. Under the terms of the agreement, Biomodels and Numira will facilitate access to each other's services to assist clients with expediting drug, biological, and device conversion from concept to clinic. Additionally, the collaboration will focus on joint optimization of modeling outcomes to maximize the predictive value and efficiency of the pre-clinical process.
The alliance brings together Biomodels' 17 years of experience in the development, biological definition, and validation of pre-clinical models with Numira's unique 3D high-resolution, quantitative microCT imaging and specialized histology services. Clients will now have the opportunity to more robustly visualize and quantify morphological signals that are associated with efficacy end-points.
"Our scientific collaborations with Numira led us to the realization that formalizing a relationship made great sense for us and our clients," said Dr. Greg Lyng, Biomodels' Director of Research. "We look forward to innovating with Numira's strong scientific team to continue our leadership in the development of clinically actionable pre-clinical models."
"By combining Biomodels' in vivo pre-clinical model expertise with Numira's strengths in ex vivo imaging and histology, we will now be able to provide seamless end-to-end solutions to our pharmaceutical customers," said Dr. David Weinstein, Numira's President & COO. "As researchers seek to get more value from their study specimens, we find they are increasingly turning to imaging and morphometric analysis as study end-points. Through our partnership with Biomodels, we will be able to provide those researchers with deeper mechanistic insights as we help them characterize and understand their models."
Biomodels (www.biomodels.com), a pre-clinical research organization founded in 1997, develops and conducts predictive translational studies for biotechnology and pharmaceutical companies, with particular expertise in the areas of oncology, cancer supportive care, radiation injury, and pulmonary, inflammatory, and autoimmune diseases. The company specializes in the development and implementation of models which are highly translatable and predictive of outcomes in humans. Biomodels' longstanding collaborations with Harvard and MIT partners provide the platform for its sophisticated mechanism of action analyses. Biomodels' demonstrated history of providing actionable data has expedited the transition from test tube to the clinic for a wide range of small molecules, biologicals, and devices.
Numira (www.numira.com) is a rapidly growing provider of specialty contract research services to the pharmaceutical and medical device industries. Through the combination of novel software technologies and unique imaging capabilities, Numira provides clients with an unmatched array of pre-clinical services for research programs in inflammation, cardiovascular, oncology, pulmonary, renal, bone, and other therapeutic areas. Numira is a recognized leader in high-resolution imaging and specialized histology services for drug and device development.
©2012 PR Newswire. All Rights Reserved.